- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a company name.
Outlook Therapeutics Inc.
Headquarters: Iselin, NJ, United States
Website: https://outlooktherapeutics....
Year Founded: 2010
Status: Public
Industry Sector: HealthTechnology
CEO: Lawrence A. Kenyon, CPA
Number Of Employees: 23
Enterprise Value: $113,860,952
PE Ratio: -1.22
Exchange/Ticker 1: NASDAQ:OTLK
Exchange/Ticker 2: N/A
Latest Market Cap: $54,638,800
BioCentury | Feb 1, 2025
Management Tracks
Daiichi Sankyo to promote Okuzawa to CEO
Plus: New chair at Outlook and an update from Elevation
BioCentury | Dec 4, 2024
Product Development
Confidence in masked T cell engagers builds with Janux update
Also in BioCentury’s Clinical Report: Cartesian’s autoimmune CAR T durability, Roivant’s miss, Novocure’s pancreatic cancer data, and more
BioCentury | Nov 15, 2023
Management Tracks
Rivus appoints Smith as chair and hires Schott as CMO
Plus: Noema and K36 hire CMOs and more from Myricx, Outlook and IMIDomics
BioCentury | Aug 30, 2023
Regulation
Aug. 30 Quick Takes: With Embark acquisition, Novo gains another obesity asset
Plus: Epigenome editing company Epigenic raises $32M series A and updates from Outlook, InflaRx, Zealand and FDA
BioCentury | Jan 21, 2023
Management Tracks
Mike Johnson named Infinant CEO
Plus CFO and COO to depart Avita and updates from Tallac and Outlook
BioCentury | Oct 28, 2022
Product Development
Oct. 28 Quick Takes: Gilead returns to $100B market cap on strong earnings
Plus: vaccines stand out for Sanofi, and updates from Outlook, PTC, Y-mAbs, Ascletis, Agios and more
BioCentury | Mar 5, 2022
Management Tracks
Entos builds out team with Chen as CMO, Ding as CBO
Plus Henderson becomes CEO of Wren, and updates from Bolt, argenx and more
BioCentury | Feb 11, 2022
Management Tracks
Silberstein joins GentiBio as CFO
Plus new CTO, CDO at Finch; and updates from Generation Bio, Atea and more
BioCentury | Aug 4, 2021
Deals
Aug. 3 Quick Takes: BeiGene picks N.J. for new campus
Plus Zentera, Iterative Scopes, BMS, Novartis, Mestag, Engrail, AbCellera-Tachyon, Outlook
BioCentury | Jul 8, 2021
Management Tracks
Chin returns to Arix to rebuild investment team as three more depart; plus ADCendo, Magenta, Junshi, Valneva, Q32 Bio, Outlook, Quotient Catalyst, Kaleido, Amolyt and more
Mark Chin is rejoining Arix Bioscience plc (LSE:ARIX) as managing director with a mandate to rebuild the VC’s investment team. Managing Director Christian Schetter, Principal John Cassidy
Items per page:
1 - 10 of 12